Abstract | RATIONALE: The present study evaluates the effect of pre-irradiation chemotherapy in pediatric patients with high risk medulloblastoma. Twenty-four (24) pediatric patients attended the pediatric unit of Kasr-El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) from January 2000 to January 2003. PATIENTS AND METHODS: Our patients were 13 boys and 11 girls aged 3-12 years with a median of 6.5 years. According to Chang staging system 6 cases had T2, 14 cases had T3 A and 4 cases had T3 B, 20 cases were M0, 3 cases were M1 and 1 case was M2. All patients were treated by initial surgery, 2 cycles of pre-irradiation chemotherapy followed by craniospinal radiation then by 4 cycles of post-radiation chemotherapy. RESULTS: Fifteen out of the 20 patients with M0 had objective response (10CR + 5PR) and no one had disease progression after pre-irradiation chemotherapy. Among 4 patients with M0 disease, 2 patients had PR and 2 had S.D. There was no disease progression among patients who received pre-irradiation chemotherapy. The 3-year overall survival and 3-year progression-free survival; (PFS) were 50% and 51%, respectively, Myelosuppression was the main toxic effect observed during pre-irradiation chemotherapy; however, there was no delay or interruption of craniospinal irradiation. CONCLUSION:
|
Authors | Hesham H Abd-El-Aal |
Journal | Journal of the Egyptian National Cancer Institute
(J Egypt Natl Canc Inst)
Vol. 18
Issue 4
Pg. 357-62
(Dec 2006)
ISSN: 1110-0362 [Print] England |
PMID | 18301459
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cerebellar Neoplasms
(drug therapy, etiology, mortality, radiotherapy)
- Child
- Child, Preschool
- Cisplatin
(administration & dosage, adverse effects)
- Combined Modality Therapy
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Male
- Medulloblastoma
(drug therapy, etiology, mortality, radiotherapy)
- Radiotherapy
- Radiotherapy, Adjuvant
- Risk Factors
- Survival Analysis
|